| Business

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Wednesday, June 4, 2014, 10:51 a.m.

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.




Show commenting policy

Most-Read Business Headlines

  1. CMU showcases its lengthy list of fledgling companies at venture event
  2. Sluggish wage growth may sap retail spending during winter holidays
  3. Last-minute China worries derailed Fed’s rate hike plans, minutes reveal
  4. Volkswagen executive Horn sidesteps blame in emissions scandal
  5. Rice, Gulfport team on Utica shale pipeline system
  6. Other segments nudge Alcoa to slim profit
  7. Power plants challenged by carbon capture and storage
  8. Energy efficiency goes mainstream with help of regulations, demand
  9. Fed insight gives stocks room to run; S&P 500 regains 2,000 mark
  10. Bear sharpens claws on ‘old Pittsburgh’
  11. Coal’s upside? Things can’t get much worse after a dire 2015